Impaired plasma lipid profiles in acute hepatitis

• Published in: Lipids in health and disease 2010-01, Vol.9 (1), p.5-5, Article 5
• Main Authors: Luo, Libo, Pu, Xiangke, Wang, Yongzhong, Xu, Ning
• Format: Article
• Language: English
• Subjects: Acute Disease; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I - blood; Apolipoproteins B - blood; Basic Medicine; Blood Coagulation; Blood lipids; Cholesterol - metabolism; Diagnosis; Farmakologi och toxikologi; Female; Hepatitis; Hepatitis - blood; Humans; Lipids - blood; Lipoprotein(a) - blood; Läkemedelskemi; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicinal Chemistry; Medicinska och farmaceutiska grundvetenskaper; Middle Aged; Pharmacology and Toxicology; Physiological aspects; Virus Diseases - blood
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/1476-511X-9-5

The present study examined plasma lipid profiles in thirty patients suffered from acute viral hepatitis. Patients' blood samples were collected at both the debut and recovery of diseases. Thirty sex and age matched normal subjects were included as controls. Plasma total triglycerides (TG), total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein AI (ApoAI), apolipoprotein B (ApoB), lipoprotein (a) (Lp(a)), blood coagulation status including prothrombin complex activity and activated partial tromboplastin time (APTT), and hepatic functions were determined by the automatic biochemical analytical instrument. It demonstrated that plasma levels of total cholesterol, HDL-C and apoAI were significantly lower in the patients at the acute phase of hepatitis than those in normal subjects, whereas plasma levels of TG and LDL-C were obviously higher in the patients than in normal subjects (P < 0.05). Moreover, we demonstrated that patients' plasma levels of total cholesterol, LDL-C, HDL-C and apoAI were lower at the active phase of the diseases than at the recovering phase, which indicating that acute liver damage could significant influence lipid metabolism in vivo. No pathological changes of blood coagulation status occurred in these patients during the study as all selected patients had moderate hepatitis. It may conclude that examinations of plasma lipid profile could be considered as a clinical index to reflect liver damage in the active phase of hepatitis.